Centogene announced that it received a notification letter from Nasdaq indicating that the company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of
Centogene announced that it received a notification letter from Nasdaq indicating that the company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of
Centogene N.V. (CNTG) has released an update. Centogene N.V., a life science company specializing in rare and neurodegenerative diseases, has been notified by Nasdaq that it is not meeting the
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from
Centogene N.V. (CNTG) has released an update. CENTOGENE N.V., a key player in data-driven solutions for rare and neurodegenerative diseases, has announced the extension of its partnership with Takeda to
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal